Condition: Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Hodgkin Lymphoma · Sponsor: National Cancer Institute (NCI)
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ASTX727 consists of the combination of decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Giving nivolumab in combination with ASTX727 may shrink and stabilize cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Chicago Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| UC Comprehensive Cancer Center at Silver Cross | New Lenox, Illinois, United States | Recruiting |
| University of Chicago Medicine-Orland Park | Orland Park, Illinois, United States | Recruiting |
| NYU Langone Hospital - Long Island | Mineola, New York, United States | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05272384